182Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Japan
Neuroscience Intelligence
Japan neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #11 of 50 · Data maturity A · Research score 43.6 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
51Recruiting trials
367Publications
276Institutions
Executive interpretation
Japan ranks #11 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC2211 recruiting
Eli Lilly and Company155 recruiting
Hoffmann-La Roche102 recruiting
Eisai Co., Ltd.91 recruiting
Takeda70 recruiting
Biogen62 recruiting
GlaxoSmithKline60 recruiting
AbbVie51 recruiting
Boehringer Ingelheim50 recruiting
Eisai Inc.44 recruiting
Disease activity
Parkinsons42trials
Alzheimers38trials
Epilepsy24trials
Neuromuscular12trials
Depression10trials
Schizophrenia7trials
Stroke6trials
Other Neurology5trials
Adhd4trials
Migraine Headache4trials
Research institutions
Takeda (Japan)OpenAlexlinked institution
Yamaguchi UniversityOpenAlexlinked institution
Utano HospitalOpenAlexlinked institution
Tottori UniversityOpenAlexlinked institution
Akita UniversityOpenAlexlinked institution
National Institutes of Natural SciencesOpenAlexlinked institution
Chugai Pharmaceutical Co., Ltd. (Japan)OpenAlexlinked institution
Tokyo Metropolitan Neurological HospitalOpenAlexlinked institution
Chiba Cancer CenterOpenAlexlinked institution
Japan Society for the Promotion of ScienceOpenAlexlinked institution
Clinical evidence trail
NCT07666022A Clinical Study to Evaluate the Safety of MF1, a New Treatment for Parkinson's Disease-related Disorders (MF1 Study)RECRUITING
NCT07589595A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RECRUITING
NCT07424404A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRECRUITING
NCT07291453Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral HabitsRECRUITING
NCT07227857A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic EncephalopathyRECRUITING
NCT07221669A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07170150A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseRECRUITING
Research evidence trail
PUBMEDEstablishment of age- and sex-stratified normative data for the Brief Assessment of Cognition (BAC) app in healthy Japanese individuals.2027-01-01
PUBMEDAmyloid-β aggregation inhibitory activity and neuroprotective effects of metabolites of Trichoderma pluripenicillatum.2027-01-01
PUBMEDBacterial constipation: Mucin-degrading intestinal commensal bacteria cause constipation.2026-12-31
PUBMEDBase editing rescues a hereditary motor neuron disease in mouse and patient-derived iPSC organoid models.2026-12-10
PUBMEDLongitudinal NODDI-DTI assessment of brain recovery following CPAP in obstructive sleep apnea: Tissue-compartment changes in white and gray matter.2026-12-01
PUBMEDM3 muscarinic receptor antagonism attenuates cocaine-induced hippocampal oligodendroglial changes and relapse-like behavior in male mice.2026-12-01
PUBMEDLongitudinal mother-rated screening of male partners' depressive symptoms using the Edinburgh postnatal depression scale during the perinatal period.2026-12-01
PUBMEDBeyond executive dysfunction: The precuneus as an introspective monitoring hub for driving safety.2026-12-01
PUBMEDDigital behavior therapy for insomnia in the general population: secondary analysis of the multi-arm RESiLIENT trial with active comparators.2026-12-01
PUBMEDAutistic-like traits and longitudinal changes in health-related quality of life among individuals with bipolar disorder: A 12-month study.2026-12-01
PUBMEDChronotype and insomnia symptoms in the incidence and persistence of depressive symptoms: An 8-year longitudinal cohort study.2026-12-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.